347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

M. Piccart,M. Ruiz Borrego,F. Duhoux,H-T. Arkenau,B. Doger de Spéville,H. Wildiers, M. Campone,D. Tosi, J. Garcia-Corbacho,B. Jimenez,S. Escrivá-de Romaní, A.M. Wardley,P. Tassone,V. Boni,Y. Jerez, P.G. Aftimos, A. Hennequin, F. Amair-Pinedo, A.U.E. Pellacani, D.O. Laurent

Annals of Oncology(2020)

引用 2|浏览1
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要